Condensed Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2012	Mar. 31, 2011
Cash flows from operating activities:
Net loss	$ (355,181)	$ (141,644)
Adjustments to reconcile net loss net cash used in operating activities:
Depreciation expense	5,236	5,287
Amortization of patents	18,921	21,305
Amortization of debt discount	1,532	699
Common stock and options issued for compensation, consulting, and vendor services	41,439	72,258
Bad debt expense	(42,326)	(12,000)
Loss on Earning on Medical Joint Venture	78,095
Changes in operating assets and liabilities:
Decrease (Increase) in accounts receivable	157,927	(483,974)
Decrease in inventories	201,321	136,239
Decrease (Increase) to advances to contract manufacturer	108,081	(512,061)
Decrease to prepaid expenses and other current assets	6,949	4,161
Decrease in other assets	7,503	16,669
(Decrease) Increase in accounts payable	(524,525)	272,193
Increase in accrued expenses and other payables	171,840	138,467
Net cash used in operating activities	(123,188)	(482,401)
Cash flows from investing activities:
Purchases of property and equipment		(2,254)
Payment for patents rights	(10,150)	(12,164)
Net cash used in investing activities	(10,150)	(14,418)
Cash flows from financing activities:
Proceeds from exercise of stock options		25,000
Proceeds from common stock	150,000
Net cash provided by financing activities	150,000	25,000
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	16,662	(471,819)
Cash and cash equivalents at beginning of period	96,324	627,082
Cash and cash equivalents at end of period	112,986	155,263
Supplemental disclosure of cash flow information:
Interest paid in cash		$ 23,000